Conference Theme
Transforming Pharma/Biotech Industries through Innovation and Partnerships

Parallel Symposia
• Seizing Opportunities in Emerging Markets
• Revitalizing Productivity in Pharma/Biotech Industries

August 6, 2011
Busch Campus Center, Rutgers University
604 Bartholomew Road, Piscataway, New Jersey 08854

www.sapaweb.org
Sino-American Pharmaceutical Professionals Association

P. O. Box 282, Nanuet, NY 10954, USA

[www.sapaweb.org](http://www.sapaweb.org)

<table>
<thead>
<tr>
<th>President</th>
<th>Jianji Wang, PhD</th>
<th>President-Elect</th>
<th>Baoguo Huang, PhD</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Secretaries</td>
<td>Yan Xia, PhD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vice President</td>
<td>Jingsong Wang, MD(GP)</td>
<td>Vice President</td>
<td>Huo Li, PhD(NE)</td>
</tr>
</tbody>
</table>

**Executive Council Members**

<table>
<thead>
<tr>
<th>Name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>BAO, Zhenhong</td>
<td>LIN, Qingcong</td>
</tr>
<tr>
<td>CAO, Ping</td>
<td>LIU, Kun</td>
</tr>
<tr>
<td>CHEN, Jiwen</td>
<td>LIU, Wansheng Jerry</td>
</tr>
<tr>
<td>CHEN, Kevin</td>
<td>SHEN, Joan</td>
</tr>
<tr>
<td>CHEN, Min</td>
<td>TOU, Derek L.</td>
</tr>
<tr>
<td>CUI, Jisong</td>
<td>TZENG, Tsang-Bin</td>
</tr>
<tr>
<td>DING, Wei</td>
<td>WANG, Jianji</td>
</tr>
<tr>
<td>FENG, Helena</td>
<td>WANG, Jingsong</td>
</tr>
<tr>
<td>FU, Helen</td>
<td>WU, Guosheng</td>
</tr>
<tr>
<td>GAO, David</td>
<td>XIA, Yan</td>
</tr>
<tr>
<td>HONG, Laura</td>
<td>XIAOHONG, Jane Xinzhen</td>
</tr>
<tr>
<td>HUANG, Baoguo</td>
<td>XIE, Charles</td>
</tr>
<tr>
<td>HUANG, Jerry X.</td>
<td>YAN, Ning</td>
</tr>
<tr>
<td>HUANG, LianFeng</td>
<td>ZHANG, Weijiang</td>
</tr>
<tr>
<td>JIN, Gang</td>
<td>ZHANG, Xiaoying</td>
</tr>
<tr>
<td>LI, Cai</td>
<td>ZHANG, Zhongda</td>
</tr>
<tr>
<td>LI, Huo</td>
<td>ZHAO, Jie</td>
</tr>
<tr>
<td>LI, Xing</td>
<td>ZHONG, Xiaotian</td>
</tr>
<tr>
<td>LIANG, Gui-Bai</td>
<td>ZHONG, Wenge</td>
</tr>
<tr>
<td>LIANG, Jun</td>
<td></td>
</tr>
</tbody>
</table>

**Board of Directors**

<table>
<thead>
<tr>
<th>Name</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CHEN, Li</td>
<td>TONG, Huayi</td>
</tr>
<tr>
<td>CUI, Jisong</td>
<td>WANG, Charles Ying</td>
</tr>
<tr>
<td>GOU, Daming</td>
<td>WANG, Jianji</td>
</tr>
</tbody>
</table>
HONG, Jun-Yan
JIN, Kewen
LI, Kechun
LI, Min
LIANG, Bo

WU, Yusheng
XIA, Mingde
XU, Rick Z.-X.
ZHANG, Hancheng
ZHANG, Zhongda

Advisory Committee Members

CHEN, Bao-lu
CHEN, Harry Huimin
CHU, Keting
GUO, Jian Zhong
HU, Jiangbin John
LEE, Junning
LI, Jian
LI, Jenny
LI, Xiaoling
LIN, Mark (Huamao)
LIN, Shiwen
LIU, Puchun
SHEN, Yongchun
SHI, Li

LIU, Cheng
MA, Bingli
WANG, DQ
WANG, Jin
WANG, John
WEI, Shifeng
WEI, Yingfei
XIANG, Jun
YAN, Li
YANG, Lihu
ZHANG, Dan
ZHANG, Yong Tony
ZHU, Jian

Former SAPA Presidents

LIU, Xiucai 1993-94 GUO, Jianzhong 2002-03
ZHANG, Guohua 1994-95 LI, Min 2003-04
HONG, Junyan 1995-96 HU, John J. 2004-05
WEI, Bill S. 1996-97 WU, Yusheng 2005-06
LIU, Puchun 1997-98 WANG, Charles Ying 2006-07
LEE, Junning 1998-99 ZHANG, Hancheng 2007-08
YANG, Lihu 1999-00 XIA, Mingde 2008-09
XU, Rick Z.-X. 2000-01 CUI, Jisong 2009-10
CHEN, Li 2001-02
# 19th SAPA Annual Conference Organizing Committee

**Conference Chair:** Dr. Jianji Wang  
**Conference Co-Chair:** Dr. Baoguo Huang

## Program

<table>
<thead>
<tr>
<th>Dr. Jianji Wang</th>
<th>Dr. Ning Yan</th>
<th>Dr. Kun Liu</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Baoguo Huang</td>
<td>Dr. Xiaole Shen</td>
<td>Dr. Yusheng Wu</td>
</tr>
<tr>
<td>Dr. Handan He</td>
<td>Dr. Weijiang Zhang</td>
<td>Dr. Huayi Tong</td>
</tr>
<tr>
<td>Dr. Kevin Chen</td>
<td>Dr. Cai Li</td>
<td>Dr. Jane Xiang</td>
</tr>
<tr>
<td>Dr. Yan Xia</td>
<td>Dr. Mingde Xia</td>
<td>Dr. Jiwen Chen</td>
</tr>
</tbody>
</table>

## Organization

<table>
<thead>
<tr>
<th>Dr. Jianji Wang</th>
<th>Dr. Mingde Xia</th>
<th>Dr. Wei Ding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Baoguo Huang</td>
<td>Dr. Xiaoying Zhang</td>
<td>Dr. Ming Chen</td>
</tr>
<tr>
<td>Dr. Jisong Cui</td>
<td>Dr. Jiwen Chen</td>
<td>Dr. Xiaohui Mei</td>
</tr>
<tr>
<td>Dr. Yan Xia</td>
<td>Dr. Kevin Chen</td>
<td>Dr. Jane Xiang</td>
</tr>
<tr>
<td>Ms. Xing Li</td>
<td>Dr. Cai Li</td>
<td>Dr. Zhenhong Bao</td>
</tr>
<tr>
<td>Ms. Helena Feng</td>
<td>Dr. Junyan Hong</td>
<td>Dr. John Qiang Tan</td>
</tr>
<tr>
<td>Dr. Helen Fu</td>
<td>Dr. Wansheng Jerry Liu</td>
<td>Dr. Gui-Bai Liang</td>
</tr>
<tr>
<td>Dr. Huayi Tong</td>
<td>Dr. Ning Yan</td>
<td>Dr. Hui Zhao</td>
</tr>
<tr>
<td>Dr. Ping Cao</td>
<td>Dr. Min Li</td>
<td></td>
</tr>
</tbody>
</table>

## Logistics

| Dr. Yan Xia | Dr. Zhenhong Bao |

## Brochure Editorial

<table>
<thead>
<tr>
<th>Ms. Xing Li</th>
<th>Dr. Jianji Wang</th>
<th>Dr. Handan He</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Wansheng Jerry Liu</td>
<td>Dr. Baoguo Huang</td>
<td>Dr. Huayi Tong</td>
</tr>
<tr>
<td>Dr. Jiwen Chen</td>
<td>Dr. Yan Xia</td>
<td>Dr. Kevin Chen</td>
</tr>
</tbody>
</table>
# Table of Contents

<table>
<thead>
<tr>
<th>Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greetings from the SAPA President</td>
<td>6</td>
</tr>
<tr>
<td>SAPA Mission Statement</td>
<td>9</td>
</tr>
<tr>
<td>About SAPA</td>
<td>9</td>
</tr>
<tr>
<td>SAPA Events – A Year in Review 2010-2011</td>
<td>10</td>
</tr>
<tr>
<td>Conference Program</td>
<td>11</td>
</tr>
<tr>
<td>Abstracts and Speaker’s Biography</td>
<td>14</td>
</tr>
<tr>
<td>SAPA Service Excellence Award</td>
<td>41</td>
</tr>
<tr>
<td>SAPA Corporate Excellence Award</td>
<td>41</td>
</tr>
<tr>
<td>2010 SAPA Scholarship &amp; Excellence in Education for Life Sciences</td>
<td>42</td>
</tr>
<tr>
<td>2010 Eli Lilly Asia Outstanding Graduate Thesis Award</td>
<td>44</td>
</tr>
<tr>
<td>2011 “Johnson &amp; Johnson Asia Outstanding Graduate Thesis Award in Bio-tech”</td>
<td>45</td>
</tr>
<tr>
<td>SAPA Corporate Sponsors</td>
<td>46</td>
</tr>
</tbody>
</table>
Greetings from the SAPA President

Jianji Wang, PhD
2010-2011 SAPA President & 19th Annual Conference Chair

Dear SAPA Members and Friends,

On behalf of the Sino-American Pharmaceutical Professionals Association (SAPA), I would like to welcome you all to the 19th SAPA Annual Conference at Rutgers University, New Jersey. Thank each of you for sacrificing family time and coming to attend and support the SAPA’s biggest annual event.

I believe we all agree that the U.S. pharmaceutical/biotech industries are facing unprecedented challenges due to various factors, such as patent expiration of blockbuster drugs, lean pipelines, reduced tolerance of risks by consumers, and ever more stringent regulatory requirements for approval of new drugs. Further, during the economic downturn in the past few years, the innovative power of the pharma/biotech industries has been significantly curbed by the limited financial resources, and many companies have been forced to downsize, rather than expand. These challenges pose a major hurdle for pharmaceutical market growth and have forced many multinational pharma/biotech companies to intensively explore opportunities in the emerging markets, such as India and China. With the population of the Chinese middle class rising, strong demand for quality medicines in China has increased pharmaceutical sales by more than 20% each year in the past ten years. This is 4 to 5 times faster than the growth rate in the U.S. According to IMS’s (Intercontinental Marketing Service) prediction, this trend will continue for many years to come, and by 2020 China will surpass the U.S. to become the No.1 country in the world in pharmaceutical sales, which in the meantime will create huge opportunities for pharma/biotech companies, including multinational U.S. companies, to grow.

To address these challenges facing the industry and help the industry grasp the new opportunities, SAPA has assembled a program for this year’s annual conference with the theme of “Transforming Pharma/Biotech Industries through Innovation and Partnerships”. During this exciting one-day event, senior executives from major multinational pharma/biotech and CRO companies as well as many other experts in this field will share their visions on the drug enterprise, with a focus on how to seize opportunities in emerging markets, and revitalize productivity in pharma/biotech industries through innovation and partnerships. This year’s program will be comprised of a plenary presentation session
until about 3:00 pm and two parallel symposium sessions from about 3:00 to 5:30 pm. The conference will be followed by a dinner banquet (Nantong Night), thanks to the generous sponsorship from the Nantong Economical Development Zone of China, I believe those of you who attend the banquet will be able to enjoy the excellent networking opportunity and make lots of new friends.

SAPA was founded in 1993 in the tri-state area and has grown rapidly into the largest professional organization of Chinese-heritage scientists in the pharma/biotech industries in the U.S., with more than 5,000 members in the US, China, Canada, Hong Kong, and Taiwan. In addition to its headquarters (SAPA-HQ) in NJ, NY, and CT tri-state area, SAPA has the New England (SAPA-NE), Greater-Philadelphia (SAPA-GP), and West (SAPA-West) three chapters, and a China Club as well as a Mid-West chapter being formed. Each year, SAPA hosts many workshops and symposia on pharma/biotech R&D, regulatory policy, and business collaboration, to fulfill its missions to promote pharmaceutical and biotech science, contribute to public health, facilitate cooperation between the US and China, and foster members’ career developments. The representative SAPA events held in the last year are highlighted in the conference brochure. It would have been impossible for SAPA to hold these successful events without the strong support and contributions from its dedicated members and leadership team as well as numerous volunteers. Each year, SAPA takes this opportunity to recognize its dedicated members for their contributions and efforts. However, due to the large number of such dedicated members, SAPA can only select the best among the best as the recipients of the SAPA Service Excellence Award to recognize their great contributions and dedication to this organization. I’m pleased to announce that fourteen SAPA members will receive the honor this year. The recipients’ names can be found in the “SAPA Service Excellence Award” section of the conference brochure. In addition, it is my great pleasure to announce that the SAPA Newsletter Team has been selected to receive a Special Recognition Award for their continued outstanding contributions. A list of its core members can be found in the “SAPA Award” section of this brochure.

To serve the communities and to encourage our younger generation to pursue interests in life sciences, since 1999 SAPA has presented a merit-based “SAPA Scholarship Award” to two or three finest high school students in the US each year. This scholarship has generated tremendous interests among bright high school students all over the country each year since its inception. This year we received many applications all from outstanding candidates, among whom three truly exceptional candidates have been selected as recipients of the scholarship award. This year we continued our administration of the “Eli Lilly Asia Outstanding Graduate Thesis Award,” which is sponsored annually by Eli Lilly to recognize the best graduate students in Asia who have made significant contributions to the field of chemistry related to life science. Twenty graduate students from twelve universities from mainland China, Hong Kong, and Taiwan have been selected as recipients of this award this year. This year, thanks to Johnson & Johnson’s generous sponsorship, we also started to administer the “Johnson & Johnson Asia Outstanding Graduate Thesis Award in Biotech,” which recognizes the best graduate students in Asia who have made significant contributions in the field of biology. Thirty graduate students from fifteen universities and research institutes have been selected as recipients of this award this year.

Our thanks go to all the sponsors for their generous sponsorship and support of SAPA activities. A list of sponsors for this year can be found in this brochure. Without their support, we would not be able to achieve our success.

I would also like to take this opportunity to thank all the speakers and panelists for sacrificing their
family time to join us at the SAPA annual conference today to share their insights with us. We deeply appreciate their great efforts and contributions to the pharmaceutical and biotech community. I hope everybody will enjoy their presentations.

Finally, I would like to thank all SAPA leadership team members, SAPA members, and volunteers for your trust and great support during the past year. It has been my great honor to serve as the president of this great organization. Thank you!

Yours truly,

Jianji Wang, PhD
SAPA President

August 6, 2011
SAPA Mission Statement

- To promote the advancement of pharmaceutical science and biotechnology
- To make contributions benefiting public health education
- To promote scientific exchange and business cooperation between US and China
- To foster the career growth of pharmaceutical and biomedical professionals

About SAPA

SAPA was founded in 1993 in the US as a non-profit organization and since then has grown rapidly and become one of the most active and well-recognized professional organizations in the US with a membership base of over 4000. SAPA is headquartered in the Greater New York area (NJ/NY/CT) with three regional chapters (SAPA-NE in New England, SAPA-GP in Greater Philadelphia, and SAPA-West in West Coast), one club in Shanghai, one club in Nanjing and a number of sponsoring cities in China, including Beijing, Shanghai, Hangzhou, Guangzhou, Nanjing, Tianjin, Suzhou, Wuxi, Jiangyin, Taizhou and Zhengzhou, etc. SAPA members are engaged in drug discovery, pre-clinical & clinical development, manufacturing, regulation, marketing, and distribution of pharmaceuticals and biotech therapeutic products. To fulfill its missions, each year SAPA and its regional chapters organize/sponsor many events including the SAPA annual conference, scientific symposia, seminars, workshops, and social activities both in the U.S. and China. These events have been supported and sponsored by many organizations, including major pharmaceutical, biotech and CRO companies as well as many Bio-Parks and Development Zones in China.

SAPA Organization Structure

**SAPA Executive Council:** President, President-Elect, Immediate-Past-President, General Secretary & 30 EC Members, Conducting SAPA daily operation, organizing SAPA events and activities.

**SAPA Board of Directors:** SAPA BD Chair and 15 SAPA Board of Directors including SAPA President & Immediate-Past-President. Setting up policies and regulations, nominating and approving SAPA officers, and guiding SAPA direction.

**SAPA Advisory Committee:** Chaired by SAPA Immediate-Past-President and over 20 AC Members. Advising, guiding and supporting.
## SAPA Events – A Year in Review 2010-2011

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aug 14, 2010</td>
<td>The 18th SAPA-HQ Annual Conference, NJ</td>
</tr>
<tr>
<td>Sep 10, 2010</td>
<td>SAPA-HQ Picnic, NJ</td>
</tr>
<tr>
<td>Oct 24, 2010</td>
<td>SAPA Presidential Forum, Beijing</td>
</tr>
<tr>
<td>Oct 25, 2010</td>
<td>Beijing HIF 2010, Beijing</td>
</tr>
<tr>
<td>Nov 10, 2010</td>
<td>Shanghai 2010 Bio-Forum, Shanghai</td>
</tr>
<tr>
<td>Jan 8, 2011</td>
<td>SAPA Career Development Workshop and New Year Party, NJ</td>
</tr>
<tr>
<td>Jan 15, 2011</td>
<td>Shenzhen Introduction Event, NJ</td>
</tr>
<tr>
<td>Feb-Apr, 2011</td>
<td>SAPA Scholarship, Lilly Awards, and J&amp;J Awards, NJ</td>
</tr>
<tr>
<td>Apr 30, 2011</td>
<td>SAPA IND Filing Workshop, NJ</td>
</tr>
<tr>
<td>May 14, 2011</td>
<td>Nanjing High Tech Park Introduction Event, NJ</td>
</tr>
<tr>
<td>May 21, 2011</td>
<td>SAPA-NE Annual Conferences, Boston</td>
</tr>
<tr>
<td>Jun 24-25, 2011</td>
<td>SAPA-GP Annual Conference, Philadelphia</td>
</tr>
<tr>
<td>Jun 1-3, 2011</td>
<td>Shanghai 2011 Bio-Forum, Shanghai</td>
</tr>
<tr>
<td>Jun 4-8, 2011</td>
<td>SAPA China Satellite City Visits: Taizhou, Yantai, and Qinhuangdao</td>
</tr>
<tr>
<td>Aug 6, 2011</td>
<td>The 19th SAPA-HQ Annual Conference, NJ</td>
</tr>
</tbody>
</table>

Please visit chapters’ websites for each chapter’s events in 2010-2011
# Conference Program

**Saturday, August 6, 2011**

**Conference Chair:** Jianji Wang, PhD, 2010-2011 SAPA President  
**Conference Co-Chair:** Baoguo Huang, PhD, 2010-2011 SAPA President-Elect

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00AM – 8:45AM</td>
<td>Registration and Breakfast</td>
</tr>
</tbody>
</table>
| 8:45AM – 2:55PM | **Plenary Session**  
(See page 14 – 23 for speaker’s biography and abstracts) |
| 8:45AM – 9:00AM   | Welcome and Opening Remarks  
Jianji Wang, PhD, 2010-2011 SAPA President  
Mr. Limin Zhou, Vice Consul General, Consulate General of the P.R. China in New York |
| 9:00AM – 9:35AM   | Innovation in Consumer Healthcare: A Recipe for Success  
Mark Gelbert, PhD, JD, Senior Vice President, Global R&D, Pfizer Consumer Healthcare |
| 9:35AM – 10:10AM  | Moving from "Made in China" to "Discovered in China"  
Jingwu Zang, MD, PhD, Senior Vice President, GlaxoSmithKline (China) R&D |
| 10:10AM – 10:45AM | Who Cares About Personalized Medicine?  
Danny R. Howard, PhD, Vice President and Global Head of PK/PD-DMPK, Novartis |
| 10:45AM – 11:00AM | Coffee Break                                                            |
| 11:00AM – 11:35AM | Can an MNC in China Address the Challenges of Global R&D?  
Ruiping Dong, MD, PhD, Senior Vice President, Emerging Markets, Merck |
| 11:35AM – 12:10PM | The Evolution of Celgene: China, The New Frontier  
Jerome B. Zeldis, MD, PhD, CMO, Celgene Corporation; CEO, Celgene Global Health |
| 12:10PM – 12:20PM | SAPA Scholarship / SAPA Election Results  
Jianji Wang, PhD, 2010-2011 SAPA President  
Baoguo Huang, PhD, 2010-2011 SAPA President-Elect |
| 12:20PM – 1:10PM  | Lunch                                                                   |
| 1:10PM – 1:45PM   | How Roche has transformed its R&D model through Innovation and Partnerships  
Jacky Vonderscher, PhD, Senior Vice President and Global Head of Translational Research Sciences, Hoffmann-La Roche |
| 1:45PM – 2:20PM    | Improving R&D Productivity Through External Partnership  
Frank Jiang, MD, PhD, Vice President and Head, Asia-Pacific R&D, Sanofi |
Future of New Drug Discovery in China
John Oyler, MBA, CEO, BeiGene, Former CEO, BioDuro, Inc.

Coffee Break

Parallel Symposia

Parallel Symposium 1: “Seizing Opportunities in the Emerging Markets”
Co-Chairs: Drs. Kevin Chen, Cai Li, Kun Liu and Ning Yan
(See page 24 – 31 for speaker’s biography and abstracts)

Strategy for Next-Generation BioPharma Company in China
Dan Guo, PhD, MBA, Executive Director, Emerging Markets, Bristol-Myers Squibb

A Global Perspective of Recent Initiatives across the Value Chain of Drug Discovery and Development
Richard Soll, PhD, Senior Vice President, Wuxiapptec

Creating Value through Partnerships
Ben Ni, PhD, Senior Director & Head of Partnering & External Innovation (China), Sanofi China

Presentation / Panel Discussions – Featuring Top Executives from Emerging Markets:
Crystal Pharmatech: Your Preferred Partner for Pharmaceutical Solid-State Research and Development Solutions
Robert Wenslow, PhD, Vice President, Business Development, Crystal Pharmatech

An Innovative Way of Drug Discovery-The Story of Icotinib & Capital Efficient Strategies
Zhaoyin Wang, PhD, Chief Science Officer, Beta Pharma

Current Status of Antibody Drug R&D in China and US
Wenzhi Tian, PhD, CEO, HuaBo Biopharm Co., Ltd.

Supporting Pharmaceutical R&D New Drug Discovery Efforts
Carl Gonzales, PhD, Director Business Development, J&W Pharmlab LLC

Biolake & Waterstone Pharmaceuticals: New Opportunity, New Start
Maximillian Yeh, VP of Strategy & Business Development, Waterstone Pharma, Wuhan BioLake

Ryan Brady, PhD, Executive Director, BioDuro
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:10PM-5:30PM</td>
<td><strong>Parallel Symposium 2: “Revitalizing Productivity in Pharma/Biotech Industries”</strong>&lt;br&gt;Co-Chairs: Drs. Handan He, Jiwen Chen, Yan Xia and Mingde Xia&lt;br&gt;(See page 32 – 40 for speaker’s biography and abstracts)</td>
</tr>
<tr>
<td>3:10PM – 3:35 PM</td>
<td><strong>3-Years of Data Points: Witnessing the Infancy of Innovative Drug R&amp;D in China</strong>&lt;br&gt;Hequn Yin, PhD, Director, Oncology Clinical Pharmacology, Novartis</td>
</tr>
<tr>
<td>3:35PM – 4:00 PM</td>
<td><strong>Nurturing the Spirit of Invention and Innovation in Biopharma for Enhanced Productivity</strong>&lt;br&gt;George Njoroge, PhD, Director, Medicinal Chemistry, Merck</td>
</tr>
<tr>
<td>4:00PM – 4:25 PM</td>
<td><strong>BIOasis Brief Introduction</strong>&lt;br&gt;Hua(Sammy) Jiang, Vice General Manager, BIOasis, Shandong International Biotechnology Park Development Co., China&lt;br&gt;&lt;br&gt;<strong>Introduction to Luye Pharma</strong>&lt;br&gt;Ting Cheng, International Business Development Manager, Luye Pharma Group Ltd., China</td>
</tr>
<tr>
<td>4:25PM – 5:30 PM</td>
<td><strong>Presentation / Panel Discussions</strong>&lt;br&gt;– Featuring Top Executives from Pharma/Biotech Industries &amp; Agencies: &lt;br&gt;&lt;br&gt;<strong>Collaborative Drug Research: A New Paradigm of Discovery</strong>&lt;br&gt;Yuguang Wang, PhD, Senior Vice President, ChemPartner&lt;br&gt;&lt;br&gt;<strong>Integrated Discovery and Development Process for A Better Pipeline and Faster Cycle-times</strong>&lt;br&gt;Tianmin Zhu, PhD, Vice President, Head of R&amp;D, Hisun Pharmaceuticals, China&lt;br&gt;&lt;br&gt;<strong>The ICH E-14 QT Guidance: The Cardiac Safety and Beyond</strong>&lt;br&gt;Jay W. Mason, MD, Chief Medical Officer, Spaulding Clinical&lt;br&gt;&lt;br&gt;<strong>Shenzhen, China’s City of Innovation and Entrepreneurship</strong>&lt;br&gt;Kristy Hua, North American Representative Office of Shenzhen(NAROS), China&lt;br&gt;&lt;br&gt;<strong>A Seamless Approach for Technology Transfer</strong>&lt;br&gt;Adnan Sabir, MS, MPharm, Vice President, Pharma Consulting Services (PCS)</td>
</tr>
<tr>
<td>5:30PM-8:00PM</td>
<td><strong>NETDA (Nantong) Night Dinner Banquet</strong>&lt;br&gt;Location: Doubletree Somerset Hotel</td>
</tr>
</tbody>
</table>
Speaker’s Biography and Abstracts

Plenary Session (8:45AM-2:55PM)

Chairs: Drs. Jianji Wang and Baoguo Huang
Mark Gelbert, PhD, JD, is Senior Vice President of Global R&D for Pfizer Consumer Healthcare and a member of the PCH Global Leadership Team. PCH is among the largest over-the-counter (OTC) health care product companies in the world. In 2010, PCH achieved sales of approximately $3.0 billion while operating globally in over 65 countries. Mark leads all aspects of the Consumer Division's Global R&D organization. He is responsible for driving and prioritizing the Division's R&D efforts to effectively bring new products to market and manage the increasingly challenging regulatory environment for OTC products.

Before joining Pfizer, Mark was Vice President of Global R&D for Johnson & Johnson Consumer Health Care. Mark has also held senior R&D positions with Pfizer Consumer Healthcare, Schering-Plough Healthcare and Novartis Consumer Healthcare. Mark has been responsible for the development of many consumer healthcare products on the shelf today, including the Rx-to-OTC switches of Claritin®, Lamisil®, Zantac®150, and Lotrimin® Ultra. Mark began his career in Product Development in Procter & Gamble’s Health Care Division. While at P&G, Mark completed his law degree and focused his efforts in Drug Regulatory Affairs. In addition to his law degree, Mark has a BA from Rutgers College, and a MS and PhD in Chemistry from the University of Massachusetts, Amherst.

“Innovation in Consumer Healthcare: A Recipe for Success”

The Global Consumer Drug market is worth over $100 billion, with China the 2nd largest market overall and one of the fastest growing. With pressure in every market on the cost of healthcare, government and consumers will turn more and more to self-care solutions to contain and manage their healthcare needs. The dynamics of this market have made it very attractive for the pharmaceutical industry and consumer goods giants alike. There are products and brands that are over 100 years old. There are mega-brands that have eclipsed $1 billion in sales. There are products and brands that are now sold in over 50 countries worldwide. The top five global consumer drug players are all multinational diversified pharmaceutical companies developing and marketing prescription drugs, over-the-counter drugs, dietary supplements and devices. The most important factor for success in consumer healthcare is Innovation. Every one of the consumer mega-brands has employed innovation to expand from minor local products to global category leaders. New successful brands have been created through innovative prescription to over-the-counter switches. And very successful brands have lost their way by a lack of innovation or unsuccessful new product launches. Innovation, itself, is a discipline, not unlike other processes we use in developing our products. Good innovation begins with insights into the consumer and the problem to be solved. This presentation will explore the innovation process as applied to consumer healthcare and highlight those factors that make for successful product development and brand growth.
Plenary Speaker: Jingwu Zang, MD, PhD, SVP, GlaxoSmithKline (China) R&D Company Ltd.

Biography

Dr. Jingwu Zang received his medical degree in Shanghai JiaoTong University School of Medicine (formerly Shanghai Second Medical University) before earning his PhD in Immunology in Belgium, where he started his illustrious pursuit of a cure for multiple sclerosis through basic and clinical research. He later received an advanced research fellowship award from the US National Multiple Sclerosis Society, and conducted his postdoctoral research on multiple sclerosis at Harvard Medical School. Dr. Zang subsequently joined the Faculty of Neurology and Immunology at Baylor College of Medicine in Texas and obtained a US medical licensure through a clinical residency program. Whilst there he was Professor of Neurology and Immunology and Research Director of the Multiple Sclerosis Center, and also the scientific founder of spin-off biotech company Opexa Pharmaceuticals.

Dr. Zang has published more than 140 scientific articles in prestigious journals, chapters and books and received many international science awards. He is well known for his pioneering work in T cell vaccination as a treatment for multiple sclerosis, which led to landmark publications in Science. In his recent career in China, Dr. Zang established both the Institute of Health Sciences (Chinese Academy of Sciences) as the founding director, and also the Institut Pasteur Shanghai (Chinese Academy of Sciences and Institut Pasteur Paris) as the Chinese founding director. Among other academic positions he held in China were Dean of the School of Medical Sciences at Shanghai JiaoTong University and Director of the Shanghai Institute of Immunology. In June 2007, Dr. Zang joined GlaxoSmithKline as Senior Vice President to head their R&D Center in China.

“Moving from ‘Made in China’ to ‘Discovered in China’”

China’s emergence as a research powerhouse has produced increasingly attractive and important prospects for foreign investment and collaboration in the field of medical science. This emergence is driven by several key factors including China’s rising economy, science and technology investment by the Government, an increasingly skilled workforce etc. Opportunities and challenges are lying side-by-side in the Chinese healthcare system and underpinning the fast-changing and dynamic landscape of Chinese R&D. GSK R&D China was established in 2007 as a global R&D center to strategically position the company in this emerging market and capitalizes on the unique opportunities and talent pool. As a leader in neuroscience drug discovery & development, GSK R&D China strives to make “Discovered in China” a reality through enhancing the innovation and introducing the culture of an entrepreneurial biotech organization in a “big pharma” setting.
Plenary Speaker: Danny R. Howard, PhD, VP and Global Head of PK/PD-DMPK, Novartis

Biography

Danny Howard received his B.S. and PhD in Pharmaceutical Sciences from the University of Missouri in Kansas City. He began his professional career working in the industry as a Biopharmaceutics consultant, and accepted his first industry position as a Clinical Scientist for Marion Merrell Dow in the Drug Dynamics group of the Clinical Pharmacokinetics Department conducting clinical pharmacology studies. He has worked across the full spectrum of both nonclinical and clinical drug development, for both biologic and small molecule therapeutics. In drug metabolism and pharmacokinetics, he has managed teams in Bioanalytical Sciences, Nonclinical and Clinical Pharmacokinetics. In 2005, he joined Novartis as the Global Head of the Pharmacokinetics and Pharmacodynamics department, where he works with teams in Switzerland, England, Japan, India, China, and the United States. He is a husband, father of three, avid reader, collector of live music, guitar-player, and home brewer.

“Who Cares About Personalized Medicine?”

At the turn of the 21st century, rapid advances in the characterization of the human genome led many to predict significant changes were on the horizon for the practice of medicine. Many claimed that knowledge of the genetic basis for disease, and the underlying pharmacogenomic contributions to drug metabolism and disposition, would revolutionize the development and discovery of new drug targets, and provide safer and more effective individualized patient treatments. It has been nearly 10 years since the code for the human genome was broken, and very little has changed in the treatment of patients. Was it all just hype? Does anyone really care about personalized medicine?
Plenary Speaker: Ruiping Dong, MD, PhD, SVP, Head of Emerging Markets, Merck

Biography

Ruiping Dong, MD, PhD, is Senior Vice President, head of Emerging Markets R&D, Merck. Dr. Dong leads new approaches for the clinical development and registration of late-stage programs so that they meet the needs of the local markets in Emerging Markets. He defines the activities that support global commercialization of branded generics, follow on biologics, vaccines, extensions of Merck's mature brands and innovative products. In addition, Dr. Dong is responsible for developing partnerships and capabilities to augment Merck’s discovery and development efforts in the emerging markets, benefit its global pipeline, boost overall productivity and differentiate the company from the competition.

While at BMS, Dr. Dong was initially responsible for R&D in Japan, later expanded to include Asia-Pacific and emerging markets. He was Vice President and head of R&D for Japan and China, BMS. Prior to joining BMS, Dr. Dong worked at AstraZeneca in several roles in Clinical Pharmacology and Oncology, including Medical Director of Oncology in the United States and Product Team Leader for IRESSA in Japan, where he led the first worldwide approval of IRESSA.

Dr. Dong earned his MD from Jiangxi Medical School in China, and his PhD from Kyushu University Medical School in Japan. Before he joined the pharmaceutical industry, he worked as a Research Fellow at the Dana-Farber Cancer Institute.

“Can an MNC in China Address the Challenges of Global R&D?”

In the last few years, industry has seen many announcements from MNCs about R&D investments in China. Lately, the nexus for these investment announcements has been India and Russia. Why are MNCs investing so liberally in these markets and what strategic advantage do they hope to achieve? The speaker will discuss these in his presentation.
Biography

Jerome B. Zeldis is CEO of Celgene Global Health and Chief Medical Officer of Celgene Corporation, Summit, NJ. Prior to that he was Celgene’s Senior Vice President of Clinical Research and Medical Affairs. He attended Brown University for an A.B., MS, followed by Yale University for an M.Phil., MD, PhD in Molecular Biophysics and Biochemistry (immunochemistry).

Dr. Zeldis was trained in Internal Medicine at the UCLA Center for the Health Sciences and Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was Assistant Professor of Medicine at the Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School and Professor of Clinical Medicine at the Robert Wood Johnson Medical School in New Brunswick, New Jersey.

Prior to working at Celgene, Dr. Zeldis worked at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical development. He has been a board member of a few start-up biotechnology companies and is currently on the board of the Semorex Corporation, NJ chapter of the Arthritis Foundation and the Castleman’s Disease Organization. He has published 112 peer reviewed articles and 24 reviews, book chapters, and editorials.

“The Evolution of Celgene: China, The New Frontier”

Celgene Corporation was a biotechnology company that became a bio-pharmaceutical company after the approval of thalidomide. Currently the company has five marketed products and is a fully integrated global bio-pharmaceutical company operating in over 70 countries. Celgene China has one marketed product and has four others in the clinical development. The vision is to conduct pan-Asian pivotal trials that will include China. Accomplishments and issues will be discussed.
Plenary Speaker: Jacky Vonderscher, PhD, SVP and Global Head of Translational Research Sciences, Hoffmann-La-Roche Inc.

Biography

Dr. Jacky Vonderscher is senior Vice President and global head of Translational Research Sciences at Hoffmann-La-Roche Inc. in Nutley N.J. His function is responsible for delivering on all technologies enabling drug targets, biomarkers and pathways analysis (genomics, genetics, proteomics, histology, imaging, bioinformatics, modeling & simulation, etc.).

Dr. Vonderscher holds an engineering degree in biological chemistry from INSA in Lyon (France) and a PhD in biochemistry from Geneva University (Switzerland). Prior to joining Roche in 2008, he held several leading positions at Novartis and Sandoz ranging from Drug Delivery Systems to Biomarker Development through Drug Metabolism and Pharmacokinetics. In 1995, he received together with 4 colleagues the golden Sandoz Triangle award for the invention and successful development of Sandimmune Neoral®. He is also a co-inventor on the patents of Mycophenolic Acid Sodium salt (Myfortic® Product) and Everolimus (Afinitor®, Zortress® and Certican® Products). In 2005-2006 he initiated 2 CRADAs with the FDA in line with the Critical Path initiative, one of them paving the way to the Predictive Safety Testing Consortium for which he served as the Industry co-Director and co-Chair of the Nephrotoxicity Working Group from its inception in March 2006 until March 2008. This led to the first submission of 7 newly qualified biomarkers of Drug Induced Kidney Injury to the FDA and EMA in a joint VXDS.

“How Roche has transformed its R&D model through Innovation and Partnerships”

As the pharma industry has struggled in the last decade to cope with decreasing productivity, high attrition rate and increasing development costs, Roche has revisited its model completely. We have bet on several new concepts ranging from Personalized HeathCare to new models of partnerships (esp. with Academic groups and small Biotechs) to rejuvenate our portfolio and to prepare for the only R&D option which will deserve a positive attitude from all our health care system partners, namely INNOVATION and DIVERSITY of approaches to significantly benefit our patients.
Plenary Speaker: Frank Jiang, MD, PhD, VP and Head, Asia-Pacific R&D, Sanofi

Biography

Dr. Jiang is Vice President of Sanofi Asia Pacific R&D and a member of corporate R&D Management Board. Dr. Jiang is responsible for developing and implementing regional R&D strategies, ensuring its performance and identifying issues and opportunities to improve healthcare in the Asia-Pacific region. Dr. Jiang joined Sanofi-Aventis in July 2002 as a Clinical Research Director and led the Lovenox Global Clinical Team, inclusive of the large phase III trial – EXTRACT. The positive outcome of this study resulted in a worldwide registration for Lovenox for STEMI indication. He moved to China in 2006 to set up China and later Asia Pacific RD organizations.

Prior to joining Sanofi-Aventis, Dr. Jiang was the Clinical Research Physician of Eli Lilly, where he led a global Phase II trial with an anti-inflammatory agent for the treatment of patients with severe sepsis. Dr. Jiang received an MD degree at Nanjing Medical College in China and a PhD in Immunology at the University of British Columbia in Canada. He is a board certified internist and currently holds a clinical assistant professorship in the Internal Medicine at Robert Wood Johnson Medical School.

“Improving R&D Productivity Through External Partnership”

Pharma R&D is under growing pressure from multiple challenges, including the low success rate in R&D, lack of predictability from animal model to human, low drug response rate/efficacy, significant increases in trial duration and costs, etc. The decline of R&D productivity makes the current business model not tenable. Breakthrough innovation is a must to solve the productivity crisis and is the key to drive R&D success at present. This presentation is to discuss the strategy on driving the innovation through external partnership, particularly in Asia Pacific Region.
**Plenary Speaker:** John Oyler, MBA, CEO, BeiGene, Former CEO, BioDuro, Inc.

**Biography**

Mr. John Oyler is a serial entrepreneur with a track record of success who has started and managed numerous life science and high technology companies. Mr. Oyler is currently a founder and CEO of BeiGene, a 75-person novel oncology R&D company in Beijing. Prior to this, Mr. Oyler co-founded and ran BioDuro, a 670 person contract research company in Beijing. Prior to its acquisition by PPD last year, BioDuro had collaborated with 8 of the top 10 pharmaceutical companies and was largely recognized as a leader in providing world-class integrated research services in China.

Mr. Oyler was previously CEO of Galenea, co-CEO of Genta, VP of Operations for Walden Laboratories, and a consultant for McKinsey & Co. in China. In addition, he founded and managed Telephia (sold to Neilson for ~ $480 million), and helped found and run two high technology companies. Mr. Oyler holds a B.S. in Engineering from The Massachusetts Institute of Technology and a MBA from Stanford Business School.

**“Future of New Drug Discovery in China”**

Despite the consultant-created, PowerPoint patent cliff charts and the talks of “over a billion dollars per drug” in expense and “the inability to make research work”, novel research is alive and well in emerging markets (specifically China), and many are quite optimistic about both its successes to date and its future potential.
Biography

Jianji is Senior Research Investigator II at BMS. He earned his B.S. degree in Chemistry from Xuzhou Normal University in 1983 and an MS degree from Nankai University in 1986. He obtained his PhD degree in Organic Chemistry from Friburg University, Switzerland in 1993. He then became a Postdoctoral Fellow in Prof. Scott’s group at Texas A & M University and Prof. Wasserman’s group at Yale University from 1993 to 1997. He joined the Process Research & Development Department, Bristol-Myers Squibb as a Research Investigator in 1998. Since then, he has been responsible for pharmaceutical lab, kilo-lab, glass-plant and pilot plant preparation of novel intermediates and drug substances. He is an author or co-author of 32 publications in peer-reviewed journals and an inventor on 7 patents. He has made numerous scientific presentations worldwide and chaired a number of international conferences/forums/symposia. Jianji is a SAPA lifetime member. He has served in SAPA leadership team as an Executive Committee Member since 2004 and General Secretary in 2009.

Biography

Baoguo Huang is a Lead Research Investigator and Head of Optimization in Molecular Innovative Therapeutics at sanofi-aventis US. He joined Aventis Pharmaceuticals in 2000. Since then, he has served as project leaders to advance many drug candidates from discovery stage to clinical phases, covering therapeutic units from Oncology, Aging, Fibrosis to Immuno-Inflammation. Baoguo is currently responsible for managing early scale-up effort and external alliances to support drug candidate nomination. In addition, he is leading a cross-functional team to implement the Design of Experiments (DoE) initiative to expedite project progression, by utilizing automation technologies along with statistical models. Baoguo received his Ph.D. from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, where he served a short tenure as a faculty. He conducted his postdoctoral research at University of California at Irvine. In addition to his scientific trainings, Baoguo attended an MBA program at SUNY Buffalo. He authored and co-authored over 30 peer-reviewed publications and patents in drug discovery, process development and bio-organic chemistry. Baoguo is a lifetime SAPA member, and the SAPA President-elect. He has organized and hosted numerous scientific symposia and business forums to promote government policies and industrial strategies, both in the US and China. He is an invited speaker for numerous international conferences.
Parallel Symposia (3:10PM - 5:30PM)

Parallel Symposium 1:
“Seizing Opportunities in the Emerging Markets”

Co-Chairs: Drs. Kevin Chen, Cai Li, Kun Liu and Ning Yan

Symposium Speaker: Dan Guo, PhD, MBA, Executive Director, Emerging Markets, Bristol-Myers Squibb

Biography

Dan Guo is currently Executive Director, Emerging Markets at Bristol-Myers Squibb. He is responsible for managing China 2020, a strategic planning initiative to build a long range plan for the company’s BioPharma success in China.

At BMS, Dan also played several commercial leadership roles in Oncology and Worldwide Pharmaceutical Strategy and Operations. Prior to BMS, Dan worked for Novartis Oncology as Director of Asia Pacific Regional Marketing while he was stationed in Singapore.

Dan holds a B.S. in Biomedical Engineering from Shanghai Medical University, an MBA from the University of Michigan, and a Ph.D. in Physiology and Biophysics from Indiana University School of Medicine.

“Strategy for Next-Generation BioPharma Company in China”

China is a major driver of global economic growth. Its pharmaceutical market in particular holds tremendous promise. China has the potential to become the third largest market for pharmaceutical products by the end of 2011 and the second largest market by 2015. Of specific importance is the industry’s innovative prescription segment, which is expected to grow even faster. Due to the unprecedented scale and velocity of healthcare modernization in China, multinational companies have considerable interest in securing long-range biopharmaceutical success in the country. Bristol-Myers Squibb has been present in China for nearly 30 years through Sino-American Shanghai Squibb, the company’s joint venture in China and the country’s first Sino-American pharmaceutical company. Our longstanding presence in China provides Bristol-Myers Squibb, a next-generation global BioPharma company, significant leverage to seize opportunities in core disease areas of importance in China. Among the success factors, local partnerships and R&D will be instrumental to the company’s growth in the country.
**Symposium Speaker:** Richard Soll, PhD, SVP, Integrated Services WuXi AppTec

**Biography**

Dr. Richard M Soll is currently Senior Vice President, Integrated Services at WuXi AppTec. In this capacity, Dr. Soll has advanced numerous programs across major target classes and therapeutic indications from hits to clinical candidates on behalf of its customers in pharma and biotech. Previously he was the Chief Scientific Officer and Vice President, R&D at the San Diego based company TargeGen where he led innovative clinical-stage drug discovery and development programs for isoform-specific PI3K inhibitors as therapeutics for inflammation, respiratory disease and cancer, multi-targeted src/VEGF inhibitors as the first topical kinase inhibitors for age-related macular degeneration and highly selective JAK2 inhibitors for the treatment of myeloproliferative disorders.

Dr. Soll was the Vice President of Chemistry at Ontogen and also founded the chemistry department at 3-Dimensional Pharmaceuticals where he served as Vice President, Chemistry. Dr. Soll’s drug discovery and development experiences span numerous clinical indications and cover a wide range of molecular targets, including inhibitors of kinases, serine proteases, GPCRs and protein-protein interactions. Through his contributions more than 7 clinical compounds have entered the clinic for cardiovascular disease, cancer, and ocular indications. Dr. Soll serves as a scientific advisory board member to biotech companies and advisor to investors. Dr. Soll has published extensively in peer reviewed journals and is an inventor of numerous issued and pending patents.

“A Global Perspective of Recent Initiatives across the Value Chain of Drug Discovery and Development”

This discussion will examine the forces and emerging solutions that are shaping the dynamic landscape of drug discovery and development from an outsourcing perspective in addition to emerging efforts of drug discovery and development in China. These strategic initiatives are designed to access new markets, improve success and productivity, stretch the R&D investments, and achieve capital efficiency. Outsourcing across the value chain form single services to integrated services is emerging as an effective, flexible solution to the ever-increasing challenges of drug discovery and development. This presentation will highlight key examples of the role that WuXi AppTec is playing in this quest.
Biography

Binhui (Ben) NI has over 18 years of pharmaceutical R&D experience in US and Asia/China. He served at senior scientific and managerial positions in several global companies in the areas of preclinical drug development and clinical operations before joining Sanofi, including Eli Lilly (US, Action group Chair), S’BIO (Chiron-Singapore JV, Singapore, VP/ head of Biology) and Covance China (General manager, China), GSK (Head of Neurodegenerative disorders) et al. Ben has >40 publications in journals including Science, PNAS and served as adjunct professors in several universities (Dept of neurology, Indiana University medical school; Dept of Anatomy and Cell biology, Indiana University Medical School) in USA and Singapore (Division of Life Sciences, University of Singapore, NUS) and also served as an advisor of WHO (World Health Organization) in neurological disorders. Ben holds a Ph. D in molecular pharmacology from University of Toronto under fellowship and post-doctoral fellowship in Clinical Pharmacology from National Institute of Mental Health with Dr. Steve M. Paul.

"Creating Value through Partnerships"

Sanofi is a diversified global healthcare leader. Increasing innovation in R&D is one of our group strategies to reach and deliver sustainable growth. China is a critical part of this Strategy. At this time of unprecedented opportunities, creative solutions and continued research collaboration are required. The new sanofi R&D values networks and focuses on partnership and collaboration. Aiming to incorporate innovation into the main fabric of R&D, we set up a unique structure revolving around networks of creativity spread across regions, technologies and scientific areas of excellence.
Presentation and Panel Discussion 1
—— Featuring Top Executives from Emerging Markets

Speaker/Panelist: Robert Wenslow, PhD, VP, Business Development, Crystal Pharmatech, Inc.

Biography
Robert Wenslow is vice president of business development at Crystal Pharmatech. Before joining Crystal Pharmatech, Robert spent 14 years at Merck. His group supported on average 30 projects per year. They contributed to salt and polymorph selection, crystallization development and optimization, preparation of registration documents, and specification setting in the area of solid-state support for both bulk drug substance and drug product.

Robert received his PhD in Analytical Chemistry from Pennsylvania State University; has presented as invited lecturer at over 10 conferences; has published over 20 peer reviewed journal articles, and is a co-inventor of over 10 patents.

“Crystal Pharmatech: Your Preferred Partner for Pharmaceutical Solid-State Research and Development Solutions”

Crystal Pharmatech is the leading dedicated solid-state research company based in China. Our executive team members each have an average of 10 years experience in top-tier pharmaceutical companies focusing on solid-state API and drug product development issues. Our researchers have extensive experience with solid-state issues from pre-clinical development through supply. We support all solid-state aspects of drug discovery, organic process development, formulation development, regulatory support, and intellectual property protection. We do not merely provide data, but also partner with customers to ensure comprehensive, integrated solutions to solve their solid-state issues. We always look for innovative collaborations with companies as well as strong job candidates to join our team. Please contact us at contact@crystalpharmatech.com or visit our website at www.crystalpharmatech.com.
Biography

Zhaoyin Wang obtained his B.Sc. from Lanzhou University in 1982 and PhD from Yale University in 1988. He then worked at Merck Frosst for 22 years and was the Director of Medicinal Chemistry. During his tenure at Merck, he published over 40 peer-reviewed scientific papers and over 30 issued US patents, and was a major inventor of both Vioxx™ and Cordaptive™. In November 2010, he joined BetaPharma as Chief Scientific Officer and established Beta Pharma Canada as a drug discovery center in Montreal focusing on treatments of inflammatory diseases and cancers.


Icotinib is a novel EGFR tyrosine kinase inhibitor discovered at BetaPharma in 2003. Through a joint-venture in China, Zhejiang BetaPharma, Icotinib has successfully passed all 3 stages of clinical studies and has been recently approved by SFDA for the treatment of non-small cell lung cancer (NSCLC). A summary of its discovery along with clinical development will be presented. In addition, other recent drug discovery activities at Beta Pharma Canada, more specifically in the areas of inhibition of multi-kinase, ALK, BCL2 and HDAC6, will also be presented.
Biography

Dr. Wenzhi Tian is the co-founder and CEO of HuaBo Biopharm Co., Ltd, a newly established drug discovery and development company in China, with a main focus of its R&D on anti-tumor antibody and protein drugs that will meet unmet medical needs both in China and global market.

Dr. Tian received his B.S. degree in clinical medicine in 1987 and MS degree in tumor immunology in 1990 from Henan Medical University. He worked as a teacher at the department of Microbiology and Immunology at Henan Medical College from 1990 to 1993. From December 1993 to July 1995, Dr. Tian joined the marketing department of Pfizer pharmaceutical company (Dalian) responsible for business development in Henan province. Dr. Tian went to Sweden in October of 1995 as a PhD candidate and moved to New York in October of 1997 for a postdoctoral position in the department of Rheumatology and Clinical Immunology of North Shore University Hospital affiliated to NYU Medical School.

From 2001 to 2005, Dr. Tian worked as a research associate at the division of immunology, department of medicine, Weill Medical College of Cornell University. From August to December of 2005, he worked as CSO in a biotech company in Shenzhen, China. Dr. Tian worked at ImClone Systems from January 2006 to April 2011 as a Research Scientist/Principal Research Associate. During the over five-year period at ImClone, Dr. Tian worked on several antibody drug candidates, of which two were granted with IND by FDA. Dr. Tian is an inventor of two patent applications, one in US and the other in China.

“Current Status of Antibody Drug R&D in China and US”

Antibody drug has been approved to be an effective and reliable treatment for a number of diseases such as inflammation and tumor. Since the launch of the first therapeutic antibody in 1986, over 30 IgGs and their derivatives have been approved for use in various indications over the past 25 years. With the advancement in molecular cloning and conjugate technology, the variety of antibody structures has been extended substantially with a main focus on multi-target antibodies, and antibody-drug conjugate (ADC) has emerged to be a hot spot in the pharmaceutical field. Thus, this presentation will discuss the current status of antibody drug R&D in the US and China and what we, as a start-up company, should do in order to catch up with the fast-growing pace in this area.
**Speaker/Panelist**: Carl Gonzales, PhD, Director, Business Development, J&W PharmLab LLC

---

**Biography**

Carl Gonzales has over 30 years of working experience in the pharmaceutical industry in marketing in-line branded Rx products and managing new product introductions, including early pre-clinical R&D efforts, development of CRO human testing protocols, and national/international new drug launches at GSK. Dr. Gonzales’s current position in business development at J&W involves identifying and developing relationships with small and medium-sized pharma companies to produce versatile organic intermediates in support of discovery efforts.

---

**“Supporting Pharmaceutical R&D New Drug Discovery Efforts”**

Development of new drugs is an urgent priority for the pharmaceutical industry, however, the cost of development has escalated and the number of new breakthrough drugs approved by the FDA has diminished. One of the answers to this problem is to outsource early compound development to overseas, such as organizations China and India, to lower costs of small quantities of new drug candidates for “proof of concept” testing in the lab before a full synthesis of the compound is undertaken. J&W PharmLab LLC specializes in custom synthesis of new organic intermediates as well as full FTE drug development services both in the US and in the Shanghai R&D facility.
Biohistory

Max Yeh is a seasoned biotech/pharmaceutical executive with international experience in drug development, manufacturing and commercialization. Prior to taking the role of VP of Strategy and Business Development at Waterstone Pharmaceuticals, he worked at several leading companies including Cambrex, CARBOGEN AMCIS, Solutia and Monsanto. In roles ranging from process engineering to executive management, he has successfully advanced programs in small molecules, high potency molecules, controlled substances, recombinant proteins, vaccines, and monoclonal antibodies.

At Waterstone Pharmaceuticals, Max is part of a highly experienced management team, led by Dr. Faming Zhang. Waterstone’s headquarters is in Carmel, IN. In 2010, Waterstone opened its new five-story Biolake R&D center and new GMP API manufacturing facility in Wuhan. Waterstone provides small molecule intermediates, advanced intermediates and APIs for development and commercial programs to an international customer base. Max graduated from Princeton University with a degree in Chemical Engineering in 1991.

“Biolake & Waterstone Pharmaceuticals: New Opportunity, New Start”

Finding the right place to build your company is a critical decision. The founder of Waterstone Pharmaceuticals, Dr. Faming Zhang, had many options to choose from for his base of operations. The Biolake (or Wuhan National Bio-Industry Base) in the Wuhan East Lake High-Tech Zone was selected for the following reasons:

- Location & talent pool
- Transportation & communication systems
- Technical schools & research focused universities
- Strong economic base
- Government services & policies
- Cost advantages versus other locations in China
- Natural beauty of the East Lake vicinity

The Biolake fosters both innovation and manufacturing in bio-medicine, bio-agriculture, medical devices and clean technology through the investment of 15 billion yuan in 3-5 years in a high-tech zone of 15 square kilometers. With this support from Biolake, Waterstone Pharmaceuticals launched its new five-story R&D facility at the Biolake Innovation Park in Wuhan on December 8, 2010.
Parallel Symposia (3:10PM - 5:30PM)

Parallel Symposium 2:  
“Revitalizing Productivity in Pharma/Biotech Industries”

Co-Chairs: Drs. Handan He, Jiwen Chen, Yan Xia and Mingde Xia

**Symposium Speaker:** Hequn Yin, PhD, Director, Oncology Clinical Pharmacology, Novartis

**Biography**

Dr. Hequn Yin is currently a Director at Novartis Oncology Clinical Pharmacology based in New Jersey, USA. Dr. Yin received B.S. in chemistry from Beijing University in 1985, MS in organic chemistry from Shanghai Institute of Organic Chemistry in 1988, and PhD in pharmacology from University of Rochester in 1995. Following a postdoc position at UC San Francisco, Dr. Yin joined the Drug Metabolism and Pharmacokinetics department (DMPK) at Hoffmann-La Roche. Since joining Novartis in 1998, Dr. Yin has served as a laboratory head, a project team representative, and a member of the cardiovascular research board. During the three year period (2007-2010) he served as a Section Head at Novartis research center in Shanghai, China (CNIBR), and successfully set up the DMPK operation. Dr. Yin can be reached at hequn.yin@novartis.com.

“3-Years of Data Points: Witnessing the Infancy of Innovative Drug R&D in China”

What are the business models by multinational pharma companies in China for drug R&D? What are the Chinese domestic pharma companies doing for innovative R&D? How conducive is the external environment (policy, regulation, talents) for innovation in China? What can we leverage for productivity? The author will share his observation and views based on the 3-year experience working at the Novartis Institute for Biomedical Research (CNIBR) in Shanghai, China.
Symposium Speaker: F. George Njoroge, PhD, Director, Medicinal Chemistry, Merck

Biography

Dr. Njoroge is a Director of Medicinal Chemistry at Merck Research laboratories. Currently, he leads medicinal chemistry programs to identify novel antiviral agents for the treatment of Hepatitis C virus. His team discovered first-in-class antiviral HCV drug Victrelis™ (also known as Boceprevir), which was approved by FDA on May 13th 2011. He has also worked extensively in the oncology area, especially in the discovery of therapeutic agents that are geared towards intervention of signal transduction process in proliferating cells. His research led to the discovery of SARASAR, a potent farnesyl protein transferase inhibitor that is currently in phase II clinical trials for treatment of Progeria.

Dr. Njoroge joined Schering-Plough Research Institute in 1988 after completion of his PhD in organic chemistry at Case Western Reserve University. Dr. Njoroge has published extensively in professional journals and is an author or co-author of more than 185 patent and scientific papers. He has received numerous awards, including Emerald Award for Professional Achievement in Industry and Thomas Alva Edison Patent Award for emerging therapies.

“Nurturing the Spirit of Invention and Innovation in Biopharma for Enhanced Productivity”

Discovering and developing new drugs is a daunting task that is expensive and requires great patience. The best current estimate puts the average cost of developing a single drug to one billion dollars. On an average, it takes more than 10 years to identify, optimize and perform clinical trials that will culminate to submission of documents for regulatory approval to market the medicine. Many of the molecules originally identified as leads (LI) eventually drop out in the early stage of this exercise. It is estimated that for every 5,000 molecules that enter LI space, only one will end up being a commercial entity – a pathetic situation in deed! In this forum, we will discuss the necessity of embracing collaborations among institutions, life science disciplines, and CRO’s in nurturing the spirit of invention and innovation with biopharmaceutical companies to obtain enhanced productivity in such a complicated arena. Recent successful collaborations that led to discovery of Victrelis™, the first HCV protease inhibitors to go to market will be discussed.
Symposium Speaker: Hua (Sammy) Jiang, MBA, Vice General Manager, BIOasis, Shandong International Biotechnology Park Development Co., Ltd.

Biography

Ms. Sammy Jiang is the Associate President of Luye Pharma Group, in charge of its group development strategy, product portfolio management and international collaborations, including business development, company alliance, and international trade. She is also the Vice General Manager of Shandong International Bioscience Park (BIOasis), in charge of overseas promotion and project introduction work. Ms. Jiang holds an MBA from Euromed Marseille Ecole de Management School (2007) and Bachelor degree in Economics from Economy School, Fudan University (1998). She is an economist certified by China National Bureau of Personnel. Ms. Jiang is a freelance writer for Healthcare Executive magazine, China Pharmaceutical Technology Economics and Management magazine and Chamber of Commerce for Import & Export of Medicines & Health Products Monthly magazine. She is also a part-time lecturer at Yantai University Pharmaceutical College.

“BIOasis Brief Introduction”

Shandong International Biotechnology Park (Bioasis) is established in collaboration by Shandong provincial government, Yantai municipal government, Yantai High-Tech Zone and Shandong Luye Pharma Group, and it is the “National Innovative Drug Breeding Bases” mainly established by Shandong Province.

Near the sea and located in the core area of Yantai High-Tech Zone, Bioasis will provide a nice, natural environment suitable for both R&D and living, which will suit the needs of scientists who wish to have a perfect work-life balance. Bioasis is scheduled to establish three major areas, i.e., R&D Area, Living Area and Marina Resort, covering 172 acres with a planned building area of 1,313,400 m² and research area of 714,800 m². Bioasis will focus mainly on the three areas of research and development: biological medicine, ocean biology, and biological agriculture.

Bioasis is designed by internationally renowned zone-design companies according to international standards and conventions. Now in the phase I of construction, the research and development area of 100,000 m² will be completed in 1 to 2 years, with the 10,000 m² laboratory space being completed in half a year, and the first-phase projects can move into the zone around August 2011. Phase II and III constructions will establish 450,000 m² biotechnology research laboratories. To attract talents from China and overseas, the zone has set up various favorable policies, such as providing seaside apartments, project start-up funds, room subsidies for research, seed fund, loan guarantee, and so on, in addition to all kinds of standard services the Zone also provides. More information about Bioasis can be found on the website www.bioasis.cn.
Biography

Graduated from China Pharmaceutical University with an MBA degree from Fudan-MIT program, Ms. Cheng has been working in the pharmaceutical and related industries for over 10 years, with experience in OTC purchase, international trading and project management. Ms. Cheng joined Luye Pharma in the middle of this year, holding the position of international BD manager.

“Introduction to Luye Pharma”

LUYE Pharma Group was established in 1994 in China and listed in SGX main board in 2004. It now has more than 2500 employees, with 1300 sales force and 300 R&D specialists.

It focuses on research, development, production and sale of Drug Delivery System (liposome and long-acting sustained release microsphere depot), biological drugs (e.g., mAbs) and Natural Drugs. Its products are involved in the fields of Oncology, Cardiovascular, Neurology, Gastroenterology, Hepatology, and Orthopaedics. Its main products include Paclitaxel liposome (anti-tumor), Sodium Glycididazole (the first approved radiotherapy sensitizer in the world), Lentinan (immuno-stimulator), Xuezhikang Capsule (lipid regulator), Sodium aescinate (anti-inflammation, anti-effusion), Elactonin (for bone pain caused by osteoporosis), Sodium Pantoprazole (for gastric ulcer), Reduced glutathione (for alcoholic hepatitis, viral hepatitis, liver fibrosis). These products had been marketed in China for several years and have entered ASEAN and Europe markets.

Additionally, there are several NCE, new formulation and antibody drugs in its product pipeline, with indications of oncology, CNS, cardiovascular and hepatology, Diabetes respectively. Entering a phase of fast growth in biological therapeutics such as monoclonal antibodies, LUYE is looking for experienced talents specialized in BioProcess Development & Operations, bioanalytical development, protein purification and cell line development.
Presentation and Panel Discussion 2
– Featuring Top Executives from Pharma/Biotech Industries & Agencies

Speaker/Panelist: Yuguang Wang, PhD, Senior Vice President, ChemPartner

Biography

Dr. Yuguang Wang is currently the Senior Vice President of Integrated Services at ChemPartner. Before ChemPartner, Dr. Wang was an Associate Director of Discovery Chemistry at Schering-Plough. Dr. Wang was at Schering-Plough for 19 years.

During the years at Schering-Plough, he was the key inventor for three clinical candidates including the thrombin receptor antagonist Vorapaxar. He received 2008 Thomas Edison Patent Award. He also managed the external collaboration at Schering-Plough. He assembled a library project team to manage library production with CROs outside US.

Dr. Wang has about 50 publications and patents.

“Collaborative Drug Research: A New Paradigm of Discovery”

The combination of higher drug research cost and fewer drug approvals enabled the decrease of productivity of drug research in big pharma companies. Many people started to think and implement new drug research strategies or paradigms.

In this talk, the paradigm of Collaborative Drug Research (CDR) will be discussed. CDR offers:
1. Utilization of the best sciences globally
2. High degree of flexibility
3. Cost saving
Biography

Dr. Tianmin Zhu is currently Corporate Vice President and Head of R&D of Zhejiang Hisun Pharmaceutical Co., Ltd. In this role, he is responsible for the entire R&D with currently 550 FTE. Prior to joining Hisun, he has served as Senior Director of Pfizer’s R&D at Pearl River, New York (formerly Wyeth Research), where he held a variety of increasingly responsible research positions in the last 16 years. Dr. Zhu graduated from Fudan University with B.S. in Chemistry and MS in Organic Synthesis. Then, he joined the Shanghai Institute of Biochemistry to explore the field of biotechnology. After he obtained his PhD in Analytical Chemistry from Rutgers, The State University of New Jersey, New Brunswick, he served as a postdoctoral fellow focusing on the drug design and delivery platforms at the Center for Advanced Biotechnology and Medicine (CABM), UMDNJ-Robert Wood Johnson Medical School, and Rutgers University before joining Wyeth in 1994.

Dr. Zhu has shown leadership through his scientific accomplishments. His contributions to the marketing of several innovative medicines globally have been awarded numerous internal and external awards including top Wyeth R&D awards, such as the Exceptional Achievement Award in 1999 and President’s Award in 2000. He was the winner of the Emerald Honors Award and named Senior Technology Fellow by Science Spectrum in 2005. He is the author of 20 peer-viewed papers, as well as the inventor of 18 US granted patents and numerous patents worldwide. His professional interests include integrating pharmaceutical R&D into the global drug development process, especially in the emerging markets, working on the technology transfer process to manufacturing internally and externally, creating diversified intellectual property platforms for innovative medicines worldwide.

“Integrated Discovery and Development Process for A Better Pipeline and Faster Cycle-times”

Zhejiang Hisun Pharmaceutical Co., Ltd. was founded in 1956. Following its mission “To be persistent in pharmaceutical innovation for humans’ wellbeing,” Hisun has been dedicated to the vision “To be a widely respected global pharmaceutical provider.” Committed to the integration of pharmaceutical R&D and manufacturing resources, Hisun has been devoted not only to provide the better-qualified APIs for customers globally but also to discover and develop new drugs. An overview of drug discovery and the development process at Hisun will be presented and discussed.
Biography

Dr. Jay Mason is the Chief Medical Officer at Spaulding Clinical (www.spauldingclinical.com), a leading Clinical Pharmacology and Cardiac Core Lab provider offering a full range of services.

Dr. Mason was an Medical Director and Director of R&D at Covance Cardiac Safety Services. He graduated from Princeton and obtained his MD degree from the University of Pennsylvania. He trained in Medicine and Cardiovascular Diseases at Stanford University Medical Center where he was a member of the Faculty from 1975 to 1983. He served as Chief of Cardiology at the University of Utah from 1983 to 1999 when he became Chairman of the Department of Medicine at the University of Kentucky. He remains a faculty member at the latter two institutions.

His clinical, teaching and research emphasis is in cardiac arrhythmias and electrophysiology. He has been awarded approximately $29M in NIH support during his research career. Dr. Mason has also served on the National Research Review Committees for the NIH, the American Heart Association and was the Chair for the Special review Committee of the NICDR. Dr. Mason is author of over 400 publications. He has also served on the editorial board of Cardiovascular Drugs and Therapy, Circulation, Annals of Internal Medicine, American Journal of Medicine and the Journal of the American College of Cardiology.

“The ICH E-14 QT Guidance: The Cardiac Safety and Beyond”

The ICH E-14 Guidance to Industry concerning assessment of the repolarization effects of new drugs has been adopted by most countries with mature pharmaceutical industry involvement. The Guidance has evolved considerably over its nearly 10 years of development and application. This presentation will review the following aspect of the guidance:

- The basis for the ICH E-14 Guidance and the thorough QT study
- History of the Guidance development
- Current status of the Guidance
- Special design and analysis considerations for thorough QT studies
- Near-term future of thorough QT studies: replacements for the moxifloxacin active control; statistical elimination of the active control
- Long-term future of the thorough QT study: eventual elimination
- Thorough blood pressure studies may be mandated
- New emphasis on benefit-harm analysis
- Definitive outcome studies beyond diabetes
**Speaker/Panelist:** Kristy Hua, Business Development Officer, North American Representative Office of Shenzhen (NAROS), China

**Biography**

Ms. Kristy Hua graduated from University of Southern California with a Master degree in Healthcare Administration. She currently works at the North American Representative Office of Shenzhen (NAROS), China, as its Business Development Officer.

---

“Shenzhen, China’s City of Innovation and Entrepreneurship”

The presentation includes a brief introduction of city of Shenzhen, its strategy and innovative environment in biopharmaceutical industry and Shenzhen’s new released ‘Peacock Plan’ on attracting high-end bio-medical talents as well as innovative teams.


Adnan Sabir is the Principal Consultant of “Pharma Consulting Services” (PCS) providing consultation in formulation/process development and technology transfer utilizing QbD/PAT tools for several pharmaceutical businesses. Recently he served as a VP and head of the Center of Excellence for Formulation Scale up in Dr. Reddy’s Laboratories in India. Prior to that Mr. Sabir served as a Scientist holding various positions in MNCs. In India he worked for Roche Products Ltd during 1978-1982 developing Saridon and Bactrim DS Tablet & Suspension. From 1985 to 1992, he worked in Solvay Pharmaceuticals on the development of various solid, liquid, and semi-solid dosages. In 1992, he joined GlaxoSmithKline (Glaxo, at the time) as a Senior Scientist in Clinical Supplies and progressed to the position of Principal Scientist of the Technology Transfer Department. Prior to joining Watson in 2004, he was a Manager at UCB (Celltech, at the time) in Rochester, NY. He has also served as an Associate Director in Process Development at Watson Laboratories Inc., in California, USA. At Watson he was responsible for the manufacturing of registration batches, scale-up, and technology transfer of Oral Contraceptive products to various manufacturing sites.

Mr. Sabir received his Master of Pharmacy degree in Pharmaceutical Technology from Nagpur University, India, in 1978, and continued to earn an MS degree in Industrial Pharmacy from the Long Island University (LIU), New York, USA, in 1985. Mr. Sabir has been an active member and a strong supporter of AAPS since 1985. He served in their Visiting Scientist Program, affiliated with the Process Development Focus Group, and has delivered lectures on Career Opportunities and other technical areas related to product development in Pharma Industries. He is also an active member of the ISPE organization currently focusing on PAT and QbD initiatives. He organized and chaired several scientific symposia at GSK, one of which was the Pharmaceutical Discussion Group of 1997, recognized as one of the very significant contribution towards knowledge transfer within GSK. Mr. Sabir is also an active member of the American Association of Indian Pharmaceutical Scientists (AAiPS).

“A Seamless Approach for Technology Transfer”

Technology Transfer is one of the key elements of the drug development process that requires a simple and efficient process. An effective Technology Transfer Process is a must for the molecule-to-market process in the competitive drug development environment. The “Ten Principles of the Technology Transfer Process” will be presented which are proven to assure successful scale-up, optimization, manufacturing, packaging, and commercial launch of the product.
SAPA Service Excellence Award

The following individuals have been selected by the Executive Council as the winners of SAPA Excellent Service Awards.

- **Special Recognition Award to the SAPA Newsletter Team**
  
  Jiwen Chen, Xing Li, Su-Fen Pu, Huayi Tong, Guosheng Wu (GP), Dapeng Chen (NE)

- **SAPA Service Excellence Award**
  
  Xiaole Shen, John Qiang Tan, Li Chen, Harry Zhang, Kevin Chen, Yan Xia, Handan He, Xin Du

SAPA Corporate Excellence Award

The following companies have been selected by the Executive Council as the winners of SAPA Corporate Excellent Awards.

- Johnson & Johnson
- Novartis
- Roche
- Celgene
- Yangtze River Pharma
- Shandong International Biotechnology (BIOasis) Park and Luye Pharma
2011 “SAPA Scholarship & Excellence in Education for Life Sciences”

The SAPA Scholarship and Excellence in Education Program was established in 1999. The Scholarship is dedicated to recognize and support excellence on the part of outstanding high school students, and to encourage the finest high school graduates to develop career in Life Sciences.

This year, SAPA received over 50 applications in the US. After 3 rounds of intensive reviews by the SAPA selection committee, the final 3 winners were announced.

Scholarship Winner: Louis Li, Monte Vista High School, Danville, CA

Biography: Louis Li is a graduate of Monte Vista High School in Danville, CA. As an avid learner, he has received various academic honors, graduating as a National Merit Scholar, AP Scholar with Distinction, and four year honor roll student. As a high school student, he remained active in scientific research. He has presented his research on ligand selection for targeted delivery of anticancer medicine and a novel nanodiagnostic method for Alzheimer’s disease at numerous research competitions. Louis has also been a five-year competitor in speech and debate, receiving awards on regional, state, and national levels. His accomplishments in a subdivision of public speaking, Extemporaneous Speaking, include placing first in the state of California and the top eight nationwide for each of the past two years. Outside of his academic endeavors, Louis has been actively involved in community service. A recipient of two President’s Volunteer Service awards, he has served as a Mathcounts coach for middle school students and a science fair mentor for elementary school students. In addition, he founded a nonprofit organization, SeniorTech, to provide free computer classes to seniors. Louis will be studying Molecular and Cellular Biology at Harvard University, where he will continue to pursue his interests in scientific research.

Scholarship Winner: David Zhao is a graduate of Montgomery High School in Skillman, New Jersey

Biography: David Zhao is a graduate of Montgomery High School in Skillman, New Jersey. He has not only tackled the most challenging classes his school offers and taken mathematics courses at Princeton University for math
majors in his senior year, but also immersed himself in activities that run the gamut. He was a Science Olympiad captain, a Science Bowl co-captain, YMCA Model United Nations Environment and Technology Committee chair, Montgomery High School Model United Nations executive board member, American Regions Mathematics League CJML B team captain, National Honor Society tutoring head, JV tennis captain, and Montgomery High School class historian. Additionally, he was a New Jersey Governor’s School in the Sciences scholar, American Legion Jersey Boys State delegate, and Presidential Scholars Award candidate. Other accolades include Chinese American Chemical Society Young Chemist Award, National AP Scholar, AP Scholar with Distinction, and Montgomery High School awards for science, mathematics, and citizenship. Satisfying his love for music, he was the principal saxophonist of the Montgomery High School Wind Ensemble and Greater Princeton Youth Orchestra Wind Symphony and the lead alto in the NJ-IAJE Region II High School Jazz Ensemble as well as the Montgomery High School Wind Ensemble treasurer. During the school year, he volunteered at the local Huaxia Chinese School to teach tennis and, during the summer, he volunteered at the local library to help run the Children’s Summer Reading Club and to help run various programs. David intends to major in chemistry at Princeton University.

Scholarship Winner: Benjamin Altman, Danbury High School, Danbury, CT

Biography: Benjamin Altman is proud to be the 16-year-old valedictorian of Danbury High School in Danbury, Connecticut, ranking first in his class of 664 since freshman year. He is a National Merit Scholarship Winner, a Connecticut Governor’s Scholar, and a National AP Scholar with 12 AP courses to his credit. He received the Rensselaer Award for Outstanding Achievement in Science and Mathematics and the Columbia University Book Award for Outstanding Academic Achievement. In school he was President of the Math Team, winning its Top Scorer award, and Captain of the Geography Team which placed 3rd in the 2011 Connecticut Geography Challenge, and 1st regionally and 6th nationally in the Academic WorldQuest competition in 2009. Benjamin has devoted many years to the study of both piano and violin, winning prizes in state piano competitions. He is an All-State violinist who played for six years in the Danbury Community Orchestra, achieving the position of concertmaster. He has also enjoyed pursuing science research, with prize-winning projects in Science Horizons and the Connecticut Science Fair three years in a row, including 1st prize in Computer Science, and awards for Excellence in Physical Science and Analytical Technique. Last summer, he was able to take his passion for research to the next level as an intern at the pharmaceutical company Boehringer Ingelheim. There, he had the privilege of experiencing the drug development process firsthand, and learning the fascinating Chemistry behind the creation of medicine. Following his passion for science and technology, Benjamin has chosen to attend the University of Pennsylvania, in the Jerome Fisher Management and Technology program, and will pursue dual degrees in Engineering and Finance.
The "Eli Lilly Asia Outstanding Graduate Thesis Award" aims to promote and recognize the best graduate students in greater China who have made significant contributions in the field of chemistry related to life sciences. After careful review by the SAPA award selection committee, twenty-one graduate students from eleven universities have been selected as recipients of this award. The award ceremony was held on June 13 as part of a one-day symposium organized by Eli Lilly in Shanghai.

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Prize</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weiwei Zi</td>
<td>Shanghai Institute of Organic Chemistry</td>
<td>1st</td>
</tr>
<tr>
<td>Xiaoyu Yang</td>
<td>Shanghai Institute of Organic Chemistry</td>
<td>1st</td>
</tr>
<tr>
<td>Wei Xia</td>
<td>University of Hong Kong</td>
<td>1st</td>
</tr>
<tr>
<td>Chang-Liang Sun</td>
<td>Peking University</td>
<td>1st</td>
</tr>
<tr>
<td>Yan Qiao</td>
<td>Peking University</td>
<td>1st</td>
</tr>
<tr>
<td>Jingjing Zhang</td>
<td>Nanjing University</td>
<td>1st</td>
</tr>
<tr>
<td>Zhiyuan Chen</td>
<td>Fudan University</td>
<td>1st</td>
</tr>
<tr>
<td>Anyuan Yin</td>
<td>Fudan University</td>
<td>1st</td>
</tr>
<tr>
<td>Lei Qiang</td>
<td>China Pharmaceutical University</td>
<td>1st</td>
</tr>
<tr>
<td>Dingyin Tao</td>
<td>Dalian Institute of Chemical Physics</td>
<td>2nd</td>
</tr>
<tr>
<td>Yanfang Liu</td>
<td>Dalian Institute of Chemical Physics</td>
<td>2nd</td>
</tr>
<tr>
<td>Tianxi He</td>
<td>Tsinghua University</td>
<td>2nd</td>
</tr>
<tr>
<td>Jun Hu</td>
<td>Tsinghua University</td>
<td>2nd</td>
</tr>
<tr>
<td>Chengjie Liu</td>
<td>Nanjing University</td>
<td>2nd</td>
</tr>
<tr>
<td>Brian Tsz Kiu LO</td>
<td>University of Hong Kong</td>
<td>2nd</td>
</tr>
<tr>
<td>Elaine Chan</td>
<td>Hong Kong Polytechnic</td>
<td>2nd</td>
</tr>
<tr>
<td>Waiting Wong</td>
<td>Hong Kong Polytechnic</td>
<td>2nd</td>
</tr>
<tr>
<td>Feng Zhang</td>
<td>China Pharmaceutical University</td>
<td>2nd</td>
</tr>
<tr>
<td>Yi Zhang</td>
<td>Shanghai Institute of Materia Medica</td>
<td>2nd</td>
</tr>
<tr>
<td>You-Sheng Cai</td>
<td>Shanghai Institute of Materia Medica</td>
<td>2nd</td>
</tr>
<tr>
<td>Xiaoyu Zhang</td>
<td>Zhejiang University</td>
<td>2nd</td>
</tr>
</tbody>
</table>
2011 “Johnson & Johnson
Asia Outstanding Graduate Thesis Award in Bio-tech”

Administered by SAPA

The "Johnson & Johnson Asia Outstanding Graduate Thesis Award in Bio-tech" aims to promote and recognize the best graduate students in Asia who have made significant contributions in the field of bio-tech related to life sciences. After careful review by the SAPA award selection committee, thirty graduate students from fifteen universities from mainland China, Hong Kong, and Singapore have been selected as recipients of this award. The award ceremony was held on June 1 as part of a one-day symposium organized by Johnson & Johnson in Shanghai.

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Prize</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wei Xu</td>
<td>Fudan University</td>
<td>1st</td>
</tr>
<tr>
<td>Kai Lei</td>
<td>Fudan University</td>
<td>1st</td>
</tr>
<tr>
<td>Fuping You</td>
<td>Peking University</td>
<td>1st</td>
</tr>
<tr>
<td>Dan Zhang</td>
<td>Tsinghua University</td>
<td>1st</td>
</tr>
<tr>
<td>Feiran Lu</td>
<td>Tsinghua University</td>
<td>1st</td>
</tr>
<tr>
<td>Kang Zou</td>
<td>Shanghai Jiao Tong University</td>
<td>1st</td>
</tr>
<tr>
<td>Didi Chen</td>
<td>Beijing Institutes of Life Science CAS</td>
<td>1st</td>
</tr>
<tr>
<td>Mo Xu</td>
<td>National Institute of Biological Sciences</td>
<td>1st</td>
</tr>
<tr>
<td>Zi Yin</td>
<td>Zhejiang University</td>
<td>1st</td>
</tr>
<tr>
<td>Xiang Li</td>
<td>Shanghai Institutes for Biological Sciences</td>
<td>1st</td>
</tr>
<tr>
<td>Shu Zhu</td>
<td>Shanghai Institutes for Biological Sciences</td>
<td>1st</td>
</tr>
<tr>
<td>Xuehui Huang</td>
<td>Shanghai Institutes for Biological Sciences</td>
<td>1st</td>
</tr>
<tr>
<td>Liuqing Yang</td>
<td>Zhejiang University</td>
<td>2nd</td>
</tr>
<tr>
<td>Feng Liu</td>
<td>Peking University</td>
<td>2nd</td>
</tr>
<tr>
<td>Yujing Zhang</td>
<td>Nanjing University</td>
<td>2nd</td>
</tr>
<tr>
<td>Fangyuan Gong</td>
<td>Nanjing University</td>
<td>2nd</td>
</tr>
<tr>
<td>Xuri Wu</td>
<td>China Pharmaceutical University</td>
<td>2nd</td>
</tr>
<tr>
<td>Yunli Yu</td>
<td>China Pharmaceutical University</td>
<td>2nd</td>
</tr>
<tr>
<td>Jun Liu</td>
<td>Beijing Institutes of Life Science CAS</td>
<td>2nd</td>
</tr>
<tr>
<td>Hua Zhang</td>
<td>Beijing Institutes of Life Science CAS</td>
<td>2nd</td>
</tr>
<tr>
<td>Wei Guo</td>
<td>Beijing Institutes of Life Science CAS</td>
<td>2nd</td>
</tr>
<tr>
<td>Jie Zhu</td>
<td>Shanghai Institutes for Biological Sciences</td>
<td>2nd</td>
</tr>
<tr>
<td>Shaohua Xu</td>
<td>National Institute of Biological Sciences</td>
<td>2nd</td>
</tr>
<tr>
<td>Yingxin Ma</td>
<td>Shanghai Jiao Tong University</td>
<td>2nd</td>
</tr>
<tr>
<td>Bao-Hong Lee</td>
<td>National Taiwan University</td>
<td>2nd</td>
</tr>
<tr>
<td>Weixuan Xu</td>
<td>National Taiwan University</td>
<td>2nd</td>
</tr>
<tr>
<td>Guoqiang Wan</td>
<td>National University of Singapore</td>
<td>2nd</td>
</tr>
<tr>
<td>Clarice Chen</td>
<td>National University of Singapore</td>
<td>2nd</td>
</tr>
<tr>
<td>Songlin Peng</td>
<td>The University of Hong Kong</td>
<td>2nd</td>
</tr>
<tr>
<td>Kato Shum</td>
<td>The University of Hong Kong</td>
<td>2nd</td>
</tr>
</tbody>
</table>
SAPA Corporate Sponsors

Roche
Nantong Economic and Technological Development Area (NETDA), Jiangsu, China
Novartis
Johnson & Johnson
Yangtze River Pharma
Luye Pharma
Shandong International Biotechnology (BIOasis) Park
SANOFI
Wuxi AppTec
Bristol-Myers Squibb
Celgene
Crystal Pharmatech
Cactus
Fox Rothschild LLP
J&W PharmaLab
Huahai US Inc.
Sundia
Beta Pharma
Hisun Pharmaceuticals
Spaulding Clinical
North American Representative Office of Shenzhen (NAROS)
Pharma Consulting Services
Bioduro
Waterstone Pharma
Wuhan Biolake
Medicilon
Ken Clark International
Eli Lilly
GenScript
Asymchem
BPBC
Pharmaron
Shang-Pharma ChemPartner
Millipore Corp
Primera Analytical Solutions
南通经济技术开发区 中国政府最早批准成立的14个国家级经济技术开发区之一，地处中国经济最发达的长三角北翼，中国沿海经济带与长江经济带交汇点，东临黄海，南濒长江，在国际大都市上海“半小时”经济圈内，所辖面积147平方公里。截止目前，全区累计开发超过50平方公里，吸引了30多个国家和地区的投资者兴办了600多家外资投资企业，其中世界500强企业超50家。

南通生物医药产业园 一个融医药研发、生产、医疗教育、医疗服务和投融资服务于一体的功能完善、配套齐全的综合性园区。园区重视技术创新，依托国家级南通出口加工区规划技术研发中心、公共实验室平台和GMP中试生产车间等基础设施，吸引医药自主创新和研发外包型企业入驻。园区规划150万平方米的医药生产用地紧邻中心商务区、配套设施建设教育科学区、会展交易区和健康医疗区。打造一条集研发、生产、应用、销售和培训于一体的医药产业链，力争成为全国乃至世界知名的医药产业园区。

Nantong Economic& Technological Development Area (NETDA)

NETDA established in December 1984, it is one of the first state-level development zones approved by the Central Government. Total area is 147 sq km. So far from now, it is already developed more than 50 sq km. More than 600 companies from over 30 regions have been invested here, including over 50 companies of Fortune top 500.

Daily certification on 150 1000 National Demonstration Zone

The top ten Development Area recognized by China’s famous investment

The best investment target for International Company

The best social security area recognized by Tango prevalence
园区介绍

山东国际生物科技园由烟台高新区委和山东绿叶制药集团有限公司共同建设，规划占地1046亩，包括科技研发区和配套区两部分。其中研发区面积566亩，设计建筑面积56万平方米。

园区采取“政府主导、企业化运作、高效率市场化运作”的运营模式，搭建创新创业平台，优化创新服务体系，着力推进生物医药，海洋生物和生物农业等高端产业的孵化及产业化。

园区已被列为“国家山东创新药物（烟台）孵化基地”、“山东省首批省级战略性新兴产业项目”以及“烟台市科技局‘六个十’重点建设项目”，并获得“中国自主创新园区创新奖”等荣誉。

截至目前，首批二十多个来自国内外的生物科技创新项目已经与园区签订协议并正式入驻园区。

Shandong International Biotechnology Park was built in collaboration by Shandong High-Tech Zone Administration Committee and Shandong Luye Pharma Group Ltd. The park, with total area of 172 acres, includes Research and Development section (R&D section) and living section, of which 54% is the R&D section and the gross floor area of the section is 560,000㎡.

Operating in corporation management with support of the local government, the park is building up innovation platform; optimizing services for innovation and promoting incubation and industrialization of senior industries such as bio-pharma; marine biology; biological agriculture; etc.; The park was included in "National innovative Drugs Incubator in Shandong Yantai", ‘the first 100 Shandong Strategy Rising Industry Projects” and "Six Ten-projects of Science and Technology Innovation in Yantai", and was honored with ‘China Proprietary Innovation Award’.

The first 20 bioscience innovation projects both domestic and abroad have signed the agreement and settled in the park by far.

Shandong International Biotechnology Park
NO.39 Keji Avenue,Yantai High-Tech Zone 264003

Tel: (86) 535-3808593  18663836033
E-mail:bioasis@luye.cn
www.bioasis.cn
Yangtze River Pharmaceutical Group is one of the largest pharmaceutical corporations in China, with over 8000 employees and annual sales of over 25 billion RMB. The corporate headquarter is based in Taizhou, Jiangsu Province. The Yangtze River has more than 20 affiliations as well as several R&D centers and manufacturing facilities located in Shanghai, Beijing, Nanjing, Guangzhou and Chengdu. The US office as the first affiliation outside China has recently been established in San Francisco, California.

Founded in 1971, Yangtze River is an R&D driven and fully integrated pharmaceutical company with its mission to safeguard all human beings by seeking innovation and progression all the time. Over the last 40 years, Yangtze River has achieved unprecedented growth in its R&D platforms, manufacturing capacities, and sales revenue. To date, it has developed a diverse portfolio of over 300 products to support wellness and prevention, as well as to treat and cure diseases across a broad range of therapeutic areas. Its products have been distributed and used by patients over 30 provinces, municipalities and autonomous regions across China, and 20 countries in Asia, Europe and Africa.

In the next five years, Yangtze River is committed to significantly increased product sales through research for innovative medicines, and through its expansion to the US and European markets. To deliver our commitment to patients and to meet our ambitious corporate goals, we are seeking top talents in the following areas including development of biopharmaceutical products, sales and marketing of dietary supplements and generic drugs, as well as regulatory affairs expertise to support product entry into U.S. We are also eager to collaborate with U.S. companies and distributors to co-promote our products and co-develop innovative drugs, as well as introduce the FDA approved drug products and medical devices into Chinese market. To meet our mission and goal, we will recruit and retain the best talents, as well as accelerate the growth through collaboration and partnership.

For further inquiry, please contact: Dr. Senping Cheng at senpingcheng@pan-pacificbiopharma.com
Sino-American Pharmaceutical Professionals Association

P. O. Box 282, Nanuet, NY 10954, USA

www.sapaweb.org